Browsing Category
Pharma Industry News
4734 posts
Business-News-Today.com section for global pharma industry news, Indian pharma sector latest news, pharma sector news today, pharmaceuticals industry news.
BrainStorm Cell Therapeutics (OTCQB: BCLI) narrows Q3 2025 loss as ALS trial preps advance and cash runway tightens
BrainStorm Cell Therapeutics narrows Q3 loss and prepares for pivotal ALS trial. Find out why 2026 could be a make-or-break year for the biotech company.
Repare Therapeutics (RPTX) to be acquired by XenoTherapeutics in CVR-backed buyout
Repare Therapeutics to be acquired by XenoTherapeutics with $1.82/share cash payout and long-term CVR upside. Find out what this means for investors.
Milvexian setback: Phase 3 Librexia ACS trial discontinued as interim data shows futility for Bristol Myers Squibb and Johnson & Johnson
Find out how the Librexia ACS trial discontinuation reshapes the future of milvexian and what it means for cardiovascular drug development today.
Merck announces acquisition of Cidara Therapeutics in bid to strengthen its infectious disease portfolio
Find out how Merck’s acquisition of Cidara Therapeutics could reshape long-acting influenza prevention and expand the company’s infectious disease pipeline.
Is Aptamer Group (LON: APTA) finally seeing sustained pharma traction with its Optimer platform?
Aptamer Group grows FY26 contracts to £1.95M with pharma repeat wins. Find out how its IP-heavy Optimer platform is gaining commercial traction.
Can reimbursement unlock the next wave of office-based cancer care? What ZUSDURI and CMS J-codes reveal about oncology’s outpatient shift
Can J-codes like ZUSDURI’s drive the next wave of office-based cancer care? Find out why 2026 could be a turning point in outpatient oncology.
Lupin (NSE: LUPIN) secures CGT exclusivity for Risperidone LAI, launches first PrecisionSphere injectable in U.S.
Lupin Limited launches Risperidone injectable in the U.S. with 180-day CGT exclusivity, marking its entry into long-acting injectables via PrecisionSphere.
Is the worst behind for Natural Capsules (NSE: NATCAPSUQ) after API delays and US tariff headwinds?
Natural Capsules reports Q2FY26 loss amid US tariff pressure and API delays. Find out if its PLI benefits and expansion plans can turn the tide.
Neurogene (NASDAQ: NGNE) advances Rett syndrome gene therapy with Embolden trial launch and positive pediatric data
Neurogene reports progress on NGN-401 Rett syndrome gene therapy with pivotal trial launch and strong pediatric data. See what’s ahead in 2026.
Cartesian Therapeutics reports 100% lupus response signal, setting up Descartes-08 for myositis expansion
Find out how Cartesian Therapeutics achieved a 100% lupus response and is driving Descartes-08 into myositis development today.